Version 1
: Received: 24 May 2022 / Approved: 25 May 2022 / Online: 25 May 2022 (09:59:26 CEST)
How to cite:
Yesilyurt, Z.E.; Karaomerlioglu, I.; Erdogan, B.R.; Ozturk, G.; Michel, M.C.; Arioglu-Inan, E. The Effects of Low-Dose Empagliflozin on Cardiac Function and Β-Adrenoceptor Responses in a Rat Model of Streptozotocin-Induced Diabetes. Preprints2022, 2022050346. https://doi.org/10.20944/preprints202205.0346.v1
Yesilyurt, Z.E.; Karaomerlioglu, I.; Erdogan, B.R.; Ozturk, G.; Michel, M.C.; Arioglu-Inan, E. The Effects of Low-Dose Empagliflozin on Cardiac Function and Β-Adrenoceptor Responses in a Rat Model of Streptozotocin-Induced Diabetes. Preprints 2022, 2022050346. https://doi.org/10.20944/preprints202205.0346.v1
Yesilyurt, Z.E.; Karaomerlioglu, I.; Erdogan, B.R.; Ozturk, G.; Michel, M.C.; Arioglu-Inan, E. The Effects of Low-Dose Empagliflozin on Cardiac Function and Β-Adrenoceptor Responses in a Rat Model of Streptozotocin-Induced Diabetes. Preprints2022, 2022050346. https://doi.org/10.20944/preprints202205.0346.v1
APA Style
Yesilyurt, Z.E., Karaomerlioglu, I., Erdogan, B.R., Ozturk, G., Michel, M.C., & Arioglu-Inan, E. (2022). The Effects of Low-Dose Empagliflozin on Cardiac Function and Β-Adrenoceptor Responses in a Rat Model of Streptozotocin-Induced Diabetes. Preprints. https://doi.org/10.20944/preprints202205.0346.v1
Chicago/Turabian Style
Yesilyurt, Z.E., Martin C. Michel and Ebru Arioglu-Inan. 2022 "The Effects of Low-Dose Empagliflozin on Cardiac Function and Β-Adrenoceptor Responses in a Rat Model of Streptozotocin-Induced Diabetes" Preprints. https://doi.org/10.20944/preprints202205.0346.v1
Abstract
Diabetes mellitus leads to cardiovascular complications including impaired cardiac β-adrenoceptor (β-AR) function. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as empagliflozin (EMPA) improve outcomes in heart failure patients and animal models thereof. Therefore, we have investigated the effects of EMPA on in vivo cardiac function (pressure-volume loop analysis) and β-AR-mediated contractile responses (papillary strips) in streptozotocin (STZ; 40 mg/kg, i.p.)-induced diabes in male Sprague Dawley rats (control, EMPA-treated control, diabetic, EMPA-treated diabetic) in a design reflecting late-onset treatment. 13-16 weeks after STZ injection treatment with a low dose of EMPA (10 mg/kg/day, daily oral gavage) or vehicle was administered for another 8 weeks. EMPA did not change cardiac function in control rats. Diabetic rats had a reduced heart rate, cardiac output, stroke work, rate of contration and rate of relaxation and increased isovolumic relaxation, whereas in vitro responses were not markedly attenuated. Treatment with EMPA showed a trend for improvement of some but not all parameters. Our results indicate that low dose EMPA treatment had limited effects on cardiac impairment despite reducing blood glucose when initiated after diabetes is manifest. Future studies with a higher dose and greater sample sizes could help to clarify the possible benefits of EMPA on the diabetic heart.
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
